Clinical Trial Update: A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) [Phase 3]

View source ↗

Summary

This document announces a Phase 3 clinical trial (MK-2870-031) evaluating sacituzumab tirumotecan for bladder/urothelial cancer, which is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Cancer

Drugs mentioned

• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Bladder Cancer | Phase 3 | Status: RECRUITING